There are a lot of things going on at the troubled Food and Drug Administration right now that could have a profound impact on the future of diabetes care, but most of us patients never hear about them. And that’s a damn shame. Because we stand at a crossroads.
You may or may not be aware that the Obama Administration is about to appoint a new FDA Commissioner. The politics and personal leanings of this…
Again, Januvia is one of the most searched-for terms on this site — which is interesting, because it’s an oral drug for controlling Type 2 diabetes with which I have no personal experience. But there’s a “perfect storm” surrounding Januvia that encapsulates many of the controversial themes running through diabetes care:
Show Me the Money
If you recall, Januvia is an oral DPP-4 inhibitor that lowers blood sugar by inhibiting glucagon release, versus the GLP-1…
Dr. Rubin, a renowned endocrinologist and author based in San Francisco, CA, has some strong opinions about the lack of ethics within drug companies, as evidenced by his last guest post here on conflict of interest. Today, in Part 2, he offers some tips on protecting yourself from exploitation.
A Guest Post by Alan L. Rubin, M. D.
In the first of two articles, I wrote about my increasing discouragement with the drug industry, particularly…
This morning Novo Nordisk announced that the FDA has scheduled an advisory committee meeting for its new Liraglutide once-daily GLP-1 drug, currently awaiting FDA approval. Believe it or not, this is huge news — with the potential to make or break a multi-billion-dollar diabetes drug category and set the tone for FDA safety proceedings in years to come.
What the FDA has done is to push off approval of Novo’s new Type 2 diabetes drug, over…
Now this is interesting. Yesterday I received an update from the folks at Manhattan Research on the “Top Pharma Product Site 2008 list” from their latest ePharma Physician® study. To be clear, this study looks at the top product sites visited by doctors, not patients or consumers:
Top 10 Product Sites Visited by Physicians in 2008
Ranked by Number of U.S. Primary Care Physician Visitors
1. Januvia
2. Actos
3. Chantix
4. Gardasil
5. Actonel
6.…